• Establishes OsteoRx, a special purpose vehicle focused on cellular regeneration, geroscience and longevity
• Acquires controlling stake in leading iPSC company RxCell Inc
• Leverages expertise of renowned scientists Dr. Xianmin Zeng and Dr. Brian Kennedy

Osteopore Limited (ASX: OSX), a global leader in 3D-printed biomimetic and bioresorbable implants, is pleased to announce the launch of OsteoRx, a new special purpose vehicle (SPV) strategically focused on cellular regeneration, geroscience and longevity science. The establishment of OsteoRx follows the completion of due diligence and all necessary approvals. Subject to conditions precedent, a controlling stake in US-based leading-edge induced pluripotent stem cell (iPSC) company RxCell Inc (RxCell) will be injected into the SPV via in-kind contribution by Dr. Xianmin Zeng and Dr. Brian Kennedy. OsteoRx will be led by Osteopore and the renowned scientists, who are internationally recognized for their expertise in stem cell biology, aging biology and translational medicine. Leveraging their expertise, the SPV will focus on accelerating breakthrough innovations that address unmet needs in age-related degeneration, chronic disease and tissue regeneration. Osteopore will provide an initial investment of AUD 0.5m to support OsteoRx's early-stage development, research, and operations, with a focus on evolving cutting-edge science into commercially viable therapies that can transform healthspan and quality-of-life. Through OsteoRx, Osteopore will have access to IP, technology, and capabilities that enable the company to expand its reach into the USD 4.39b scaffold-based cell therapy market, building on the collaboration with RxCell in October 2024. This move also reinforces Osteopore's leadership in regenerative medicine and deepens the company's exposure to the USD 19.34b stem cell market, projected to reach USD 55.75b by 2032.

This strategic move reinforces Osteopore's leadership in regenerative medicine while expanding its reach across upstream biotech and medtech. The investment also deepens Osteopore's exposure to the USD 19.34b stem cell market, projected to reach USD 55.75b by 2032, at a CAGR of 16.3%.